ASURE SOFTWARE INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ASURE SOFTWARE INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $3.08M | Mar 19, 2019 |
| FY2018 | Dec 31, 2017 | $54.44M | Mar 19, 2019 |
| FY2017 | Dec 31, 2016 | $35.54M | Mar 16, 2018 |
| FY2016 | Dec 31, 2015 | $26.91M | Mar 20, 2017 |
| FY2015 | Dec 31, 2014 | $27.21M | Mar 30, 2016 |
| FY2014 | Dec 31, 2013 | $25.47M | Mar 27, 2015 |
| FY2013 | Dec 31, 2012 | $19.97M | Mar 27, 2014 |
| FY2012 | Dec 31, 2011 | $10.94M | Apr 1, 2013 |
| FY2011 | Dec 31, 2010 | $10.03M | Mar 30, 2012 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $119.08M | Feb 26, 2024 |
| FY2023 | Dec 31, 2022 | $95.83M | Feb 26, 2024 |
| FY2021 | Dec 31, 2021 | $76.06M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $65.51M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $73.15M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $63.63M | Mar 16, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $94.87M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $82.11M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $85.54M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $62.51M | Feb 26, 2024 |
| FY2021 | Dec 31, 2021 | $46.56M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $38.09M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $43.31M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $39.50M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $41.82M | Mar 19, 2019 |
| FY2017 | Dec 31, 2016 | $27.43M | Mar 16, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($13.13M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($11.77M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($9.21M) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | ($14.47M) | Feb 26, 2024 |
| FY2021 | Dec 31, 2021 | $3.19M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | ($16.31M) | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $30.00M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | ($7.55M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | ($5.72M) | Mar 19, 2019 |
| FY2017 | Dec 31, 2016 | ($972.0K) | Mar 16, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($8.41M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($10.74M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($3.00M) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | ($11.31M) | Feb 26, 2024 |
| FY2021 | Dec 31, 2021 | ($12.96M) | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | ($14.89M) | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | ($50.40M) | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | ($10.74M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | ($1.00M) | Mar 19, 2019 |
| FY2017 | Dec 31, 2016 | $1.23M | Mar 16, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.60M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $7.81M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $6.85M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $6.15M | Feb 26, 2024 |
| FY2021 | Dec 31, 2021 | $5.41M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $5.96M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $5.35M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $6.00M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $4.46M | Mar 19, 2019 |
| FY2017 | Dec 31, 2016 | $2.90M | Mar 16, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $36.34M | Mar 11, 2021 |
| FY2020 | Dec 31, 2019 | $41.54M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $36.77M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $33.89M | Mar 19, 2019 |
| FY2017 | Dec 31, 2016 | $21.05M | Mar 16, 2018 |
| FY2016 | Dec 31, 2015 | $14.96M | Mar 20, 2017 |
| FY2015 | Dec 31, 2014 | $14.00M | Mar 30, 2016 |
| FY2014 | Dec 31, 2013 | $13.25M | Mar 27, 2015 |
| FY2013 | Dec 31, 2012 | $11.80M | Mar 27, 2014 |
| FY2012 | Dec 31, 2011 | $6.20M | Apr 1, 2013 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $22.22M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $9.39M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $18.90M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $13.67M | Feb 26, 2024 |
| FY2021 | Dec 31, 2021 | $1.38M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $2.24M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | ($4.12M) | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | ($7.13M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | ($36.0K) | Mar 19, 2019 |
| FY2017 | Dec 31, 2016 | ($2.01M) | Mar 16, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $787.0K | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $692.0K | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $1.59M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $2.32M | Feb 26, 2024 |
| FY2021 | Dec 31, 2021 | $133.0K | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $857.0K | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $1.02M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $1.90M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $1.40M | Mar 19, 2019 |
| FY2017 | Dec 31, 2016 | $436.0K | Mar 16, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $531.42M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $436.64M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $443.87M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $419.91M | Feb 26, 2024 |
| FY2021 | Dec 31, 2021 | $433.25M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $514.00M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $320.07M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $361.10M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $203.31M | Mar 19, 2019 |
| FY2017 | Dec 31, 2016 | $85.82M | Mar 16, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $333.62M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $239.32M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $252.21M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $274.84M | Feb 26, 2024 |
| FY2021 | Dec 31, 2021 | $275.01M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $368.35M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $182.49M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $258.58M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $139.54M | Mar 19, 2019 |
| FY2017 | Dec 31, 2016 | $67.58M | Mar 16, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $197.80M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $197.32M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $191.66M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $145.07M | Feb 26, 2024 |
| FY2021 | Dec 31, 2021 | $158.24M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $145.65M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $137.58M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $102.52M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $63.77M | Mar 19, 2019 |
| FY2017 | Dec 31, 2016 | $18.25M | Mar 16, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $115.76M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $94.72M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $86.01M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $86.01M | Feb 26, 2024 |
| FY2021 | Dec 31, 2021 | $86.01M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $73.96M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $68.70M | Mar 11, 2021 |
| FY2020 | Dec 31, 2018 | $99.11M | Mar 11, 2021 |
| FY2019 | Dec 31, 2017 | $67.30M | Mar 16, 2020 |
| FY2017 | Dec 31, 2016 | $26.26M | Mar 16, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($320.35M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($307.23M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($290.44M) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | ($281.23M) | Feb 26, 2024 |
| FY2021 | Dec 31, 2021 | ($266.76M) | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | ($269.95M) | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | ($253.64M) | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | ($283.64M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | ($277.60M) | Mar 19, 2019 |
| FY2017 | Dec 31, 2016 | ($271.88M) | Mar 16, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $25.24M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $21.43M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $30.32M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $17.01M | Feb 26, 2024 |
| FY2021 | Dec 31, 2021 | $13.43M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $28.58M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $28.83M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $15.44M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $27.79M | Mar 19, 2019 |
| FY2018 | Dec 31, 2016 | $12.77M | Mar 19, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $67.63M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $12.72M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $4.31M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $34.90M | Feb 26, 2024 |
| FY2021 | Dec 31, 2021 | $35.03M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $24.54M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $26.71M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $111.37M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $75.87M | Mar 19, 2019 |
| FY2017 | Dec 31, 2016 | $30.04M | Mar 16, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Feb 26, 2024 |
| FY2021 | Dec 31, 2021 | 0 | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | (1) | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | 1 | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Mar 19, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Mar 16, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Feb 26, 2024 |
| FY2021 | Dec 31, 2021 | 0 | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | (1) | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | 1 | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Mar 19, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Mar 16, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 28.08M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 26.67M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 25.00M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | 20.24M | Feb 26, 2024 |
| FY2021 | Dec 31, 2021 | 20.03M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | 18.97M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | 15.71M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | 15.28M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | 12.49M | Mar 19, 2019 |
| FY2017 | Dec 31, 2016 | 8.52M | Mar 16, 2018 |